Vaccine technology cannot be easily shared between manufacturers, says Oxford jab professor

Calls are growing for intellectual property rights to be waived and vaccine blueprints shared between companies, but experts warn Samuel Lovett that this is ‘easier said than done’

Wednesday 05 May 2021 19:07
Comments
<p>AstraZeneca is already working with more than 20 partners across 15 countries to manufacture its jab</p>

AstraZeneca is already working with more than 20 partners across 15 countries to manufacture its jab

Leer en Español

The professor who designed the Oxford/AstraZeneca vaccine has challenged the suggestion that the technology and methods for producing the Covid-19 jabs can be easily transferred from one manufacturer to another.

Sarah Gilbert, a professor of vaccinology at Oxford University, said there were multiple challenges involved in exchanging vaccine ‘blueprints’ between pharmaceutical companies, from maintaining safety production standards at factories to ensuring high yields are maintained.

As calls grows for intellectual property rights to be waived, with the World Health Organisation notably calling on manufacturers to share their technology to “dramatically increase the global supply”, other experts have warned these proposals are “easier said than done”.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in